This episode reviews major updates in lipid management for ASCVD risk reduction. Topics include revised LDL-C estimation equations, expanded clinical application of apolipoprotein B for residual atherogenic risk assessment, universal lipoprotein(a) screening, and cardiovascular kidney metabolic syndrome as a risk enhancing condition. The episode also discusses triglyceride referral thresholds, reproductive and inflammatory ASCVD risk enhancers, high sensitivity C-reactive protein guided statin considerations, and the role of coronary artery calcium scoring in refining lipid lowering therapy and cardiovascular risk stratification.